Indications and uses
For the treatment oa acne
For the treatment oa acne
use daily to get clear skin. clean the skin thoroughly before applying this product. cover the entire affected area one to three times daily. because excessive drying of te skin may occur ,start with one application daily ,then gradually increase to two or three times daily if needed or as directed by a doctor. if bothersome dryness or peeling occurs,reduce application to once a day or every other day. throw away ...
salicylic acid 0.5%
Acne treatment
For the treatment oa acne
For external use only.
Ask a doctor or pharmecist before use if you are using other topical acne medications at the same time or immediately following use of this product.
When using this product
skin irritaiton and dryness is more likely to occur if you use another topical acne medication at the same time.if irritation occurs.
only use one topical acne medication at a time.
avoid contact with eyes,if contact occurs,rlush rhoroughly with water.
If swallowed, get medical help or contact a Poison Control Center right away.
use daily to get clear skin.
clean the skin thoroughly before applying this product.
cover the entire affected area one to three times daily.
because excessive drying of te skin may occur ,start with one application daily ,then gradually increase to two or three times daily if needed or as directed by a doctor.
if bothersome dryness or peeling occurs,reduce application to once a day or every other day.
throw away cloth (do not flush)
store at room temperture.
Water, salicylic acid,Cetearyl isononanoate,Ceteareth-20,fragrance,Cetearyl alcohol,Glyceryl stearate,glycerin,Ceteareth-12,Cetyl palmitate,Propylene glycol,methylparaben,Disodium EDTA,Propylparaben,2-bromo-2-nitropropane-1,3-diol
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 42255-603-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-9c61-f424-e053-dadaa90a57ce | Acne wipes 30ct 603 |
| 42255-603-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-9c61-f424-e053-dadaa90a57ce | Acne wipes 30ct 603 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 42255-603-01 | Acne wipes | 0.675 g in 1 POUCH | SWAB | 0.675 | 4 | |
| 42255-603-01 | Acne wipes | 40 in 1 PACKAGE | SWAB | 40 | 4 | |
| 42255-603-02 | Acne wipes | 0.675 g in 1 POUCH | SWAB | 0.675 | 4 | |
| 42255-603-02 | Acne wipes | 30 in 1 PACKAGE | SWAB | 30 | 4 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| salicylic acid | ACTIVE INGREDIENT | O414PZ4LPZ | 3 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 3 | |
| 2-BROMO-2-NITROETHANOL | INACTIVE INGREDIENT | FA22WV2B2Z | 3 | |
| Ceteareth-12 | INACTIVE INGREDIENT | 7V4MR24V5P | 3 | |
| CETEARETH-2 PHOSPHATE | INACTIVE INGREDIENT | 8NSU66JGZR | 3 | |
| Cetearyl isononanoate | INACTIVE INGREDIENT | P5O01U99NI | 3 | |
| CETYL ACETATE | INACTIVE INGREDIENT | 4Q43814HXS | 3 | |
| Cetyl palmitate | INACTIVE INGREDIENT | 5ZA2S6B08X | 3 | |
| DISODIUM EDTA-COPPER | INACTIVE INGREDIENT | 6V475AX06U | 3 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 3 | |
| GLYCERYL STEARATE CITRATE | INACTIVE INGREDIENT | WH8T92A065 | 3 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 3 | |
| Propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 3 | |
| Propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 3 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 42255-603 | 42255-603-01, 42255-603-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CETEARYL ISONONANOATE | P5O01U99NI | IACT |
| CETEARETH-2 PHOSPHATE | 8NSU66JGZR | IACT |
| CETYL ACETATE | 4Q43814HXS | IACT |
| GLYCERYL STEARATE CITRATE | WH8T92A065 | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| CETEARETH-12 | 7V4MR24V5P | IACT |
| CETYL PALMITATE | 5ZA2S6B08X | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| DISODIUM EDTA-COPPER | 6V475AX06U | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| 2-BROMO-2-NITROETHANOL | FA22WV2B2Z | IACT |
| WATER | 059QF0KO0R | IACT |
| SALICYLIC ACID | O414PZ4LPZ | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| methylparaben | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / ORAL | 64 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CONCENTRATE / ORAL | 12 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | TABLET, CHEWABLE / ORAL | 0.14 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAMUSCULAR | 95 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | EMULSION / TOPICAL | 0.06 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / INTRAVENOUS | 5 %w/v | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / RESPIRATORY (INHALATION) | 25 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAMUSCULAR | 0.02 %w/v | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, COATED / ORAL | 25 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INFILTRATION | 0.35 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | AEROSOL, FOAM / TOPICAL | 0.04 %w/w | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / AURICULAR (OTIC) | NA | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / OPHTHALMIC | 1.5 %w/v | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | TABLET, EXTENDED RELEASE / ORAL | 0.12 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / TOPICAL | 24 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | JELLY / TOPICAL | 20 %w/w | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | JELLY / TOPICAL | 180 mg | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SYSTEM / TOPICAL | 42 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| Propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RECTAL | 0.02 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| Propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / ORAL | 29008 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 623ffcc6-81a7-b41e-e053-2991aa0a4cdf | 65b239cd-0374-48d7-a99e-e9bacc785939 | 2018-01-08 | Warnings | 623ffcc6-81a7-b41e-e053-2991aa0a4cdf 65b239cd-0374-48d7-a99e-e9bacc785939 |
Adverse event summaries are temporarily unavailable. Other product information remains available.